In this episode, we review three more articles from the Jan-Feb 2020 issue of AllergyWatch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
- Altered Viscosity of Nasal Secretions in Postnasal Drip
- Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a “hit-and-run” mechanism
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
- Dr. Lee has nothing to disclose.
- Dr. Kalangara has nothing to disclose.
- Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
We’re pleased to introduce CME credit for this episode of AllergyTalk! Get credit for this episode.
ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.